Press Detail





News: Biotest AG: Biotest AG: Annual general meeting approves payout of dividend

News: Biotest AG / Key word(s): AGM/EGM
Biotest AG: Biotest AG: Annual general meeting approves payout of dividend

30.08.2017 / 14:45
The issuer is solely responsible for the content of this announcement.



PRESS RELEASE

Biotest AG: Annual general meeting approves payout of dividend

- Dividend payout of EUR 0.05 per ordinary share and EUR 0.07 per preference
share

Dreieich/ Frankfurt a. M., 30 August 2017. At the annual general meeting
(AGM) held on 30 August 2017 in Frankfurt/ Main, shareholders of Biotest AG
approved the payment of a dividend. With 79.6 percent of the ordinary share
capital represented at the meeting, a payment of EUR 0.05 per ordinary share
and EUR 0.07 per preference share was resolved with a high degree of
approval. The overall dividend payment will amount to EUR 2.4 million.

The annual general meeting, with 182 shareholders present, formally
discharged the members of the Management Board and Supervisory Board for
financial year 2016.

The full text of the speech given by the CEO of Biotest AG, Dr. Bernhard
Ehmer, at the AGM is available at:
http://www.biotest.com/de/en/investor_relations/shareholders_meeting_2017.cfm

Today it was also announced that the third project - milestone of the
Biotest Next Level (BNL) project was reached lst week with the successful
GMP * inspection by the competent authority (Regierungspräsidium Darmstadt).
A successful acceptance of the inspection is a prerequisite for a permission
of the laboratory operation and thus part of the manufacturer's license. The
new BNL laboratories were classified as GMP*-adequate and were released with
immediate effect without restrictions.

GMP*= Good manufacturing practice

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,400
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




30.08.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


605409 30.08.2017